Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

Compare

23 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VX1 Analyst Ratings

Moderate Buy

16 Buy

6 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Vertex

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VX1 Stock 12 Month Forecast

Average Price Target

€436.64

▲(13.11% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €436.64 with a high forecast of €515.04 and a low forecast of €353.03. The average price target represents a 13.11% change from the last price of €386.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"329":"€329","516":"€516","375.75":"€375.8","422.5":"€422.5","469.25":"€469.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":515.04283168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€515.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":436.6437622352,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€436.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":353.02604688,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€353.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[329,375.75,422.5,469.25,516],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,368.7,379.95714089846155,391.21428179692305,402.4714226953846,413.72856359384616,424.98570449230766,436.2428453907692,447.4999862892307,458.7571271876923,470.01426808615383,481.27140898461533,492.5285498830769,503.7856907815384,{"y":515.04283168,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,368.7,373.9264432488615,379.15288649772305,384.3793297465846,389.60577299544616,394.8322162443077,400.0586594931692,405.28510274203074,410.5115459908923,415.7379892397538,420.96443248861533,426.1908757374769,431.41731898633844,{"y":436.6437622352,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,368.7,367.4943112984615,366.28862259692306,365.0829338953846,363.87724519384614,362.6715564923077,361.4658677907692,360.2601790892308,359.05449038769234,357.8488016861539,356.6431129846154,355.43742428307695,354.2317355815385,{"y":353.02604688,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":443.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":453.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":384.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€515.04

Average Price Target€436.64

Lowest Price Target€353.03

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tazeen Ahmad

Bank of America Securities

€479.52→€486.34

Buy

25.98%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Gets a Buy from Bank of America Securities

Louise Chen

Scotiabank

€421.61

Buy

9.21%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Scotiabank

Mohit Bansal

Wells Fargo

€391.8→€438.64

Buy

13.62%

Upside

Reiterated

12/10/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo

Myles Minter

William Blair

Buy

―

Reiterated

12/05/25

Vertex Pharmaceuticals Positioned for Blockbuster Success in Rare Disease Market with Strong Renal Franchise and Promising Clinical Data

Evan Seigerman

BMO Capital

€451.42

Buy

16.93%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals: Strong Market Position and Promising Growth Potential Justify Buy Rating

Geoff Meacham

Citi

€489.74

Buy

26.86%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi

Terence Flynn

Morgan Stanley

€439.49→€480.38

Buy

24.43%

Upside

Upgraded

12/05/25

Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating

Salveen Richter

Goldman Sachs

€514.44

Buy

33.26%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals: Promising Advancements in Kidney Disease Treatments Drive Buy Rating

Cory Kasimov

Evercore ISI

€404.57

Buy

4.80%

Upside

Reiterated

11/12/25

Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Naz Rahman

Maxim Group

Hold

―

Reiterated

11/11/25

Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Joon Lee

Truist Financial

Buy

―

Reiterated

11/10/25

Analysts' Top Healthcare Picks: Dyadic International (DYAI), REPRO-MED Systems (KRMD)

Andrew Fein

H.C. Wainwright

€407.13

Buy

5.46%

Upside

Reiterated

11/10/25

Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development

Joseph Stringer

Needham

Hold

―

Reiterated

11/10/25

Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data

Gena Wang

Barclays

€352.62

Hold

-8.66%

Downside

Reiterated

11/10/25

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Paul Matteis

Stifel Nicolaus

Hold

―

Reiterated

11/09/25

Vertex Pharmaceuticals: Promising Data Amidst Competitive Renal Landscape and Investment Complexities

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tazeen Ahmad

Bank of America Securities

€479.52→€486.34

Buy

25.98%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Gets a Buy from Bank of America Securities

Louise Chen

Scotiabank

€421.61

Buy

9.21%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Scotiabank

Mohit Bansal

Wells Fargo

€391.8→€438.64

Buy

13.62%

Upside

Reiterated

12/10/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo

Myles Minter

William Blair

Buy

―

Reiterated

12/05/25

Vertex Pharmaceuticals Positioned for Blockbuster Success in Rare Disease Market with Strong Renal Franchise and Promising Clinical Data

Evan Seigerman

BMO Capital

€451.42

Buy

16.93%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals: Strong Market Position and Promising Growth Potential Justify Buy Rating

Geoff Meacham

Citi

€489.74

Buy

26.86%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi

Terence Flynn

Morgan Stanley

€439.49→€480.38

Buy

24.43%

Upside

Upgraded

12/05/25

Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating

Salveen Richter

Goldman Sachs

€514.44

Buy

33.26%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals: Promising Advancements in Kidney Disease Treatments Drive Buy Rating

Cory Kasimov

Evercore ISI

€404.57

Buy

4.80%

Upside

Reiterated

11/12/25

Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Naz Rahman

Maxim Group

Hold

―

Reiterated

11/11/25

Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Joon Lee

Truist Financial

Buy

―

Reiterated

11/10/25

Analysts' Top Healthcare Picks: Dyadic International (DYAI), REPRO-MED Systems (KRMD)

Andrew Fein

H.C. Wainwright

€407.13

Buy

5.46%

Upside

Reiterated

11/10/25

Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development

Joseph Stringer

Needham

Hold

―

Reiterated

11/10/25

Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data

Gena Wang

Barclays

€352.62

Hold

-8.66%

Downside

Reiterated

11/10/25

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Paul Matteis

Stifel Nicolaus

Hold

―

Reiterated

11/09/25

Vertex Pharmaceuticals: Promising Data Amidst Competitive Renal Landscape and Investment Complexities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

1 Month

xxx

Success Rate

24/32 ratings generated profit

Average Return

+3.79%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +3.79% per trade.

3 Months

xxx

Success Rate

20/29 ratings generated profit

Average Return

+6.79%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.97% of your transactions generating a profit, with an average return of +6.79% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

24/32 ratings generated profit

Average Return

+15.43%

reiterated a buy rating last month

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +15.43% per trade.

2 Years

xxx

Success Rate

27/31 ratings generated profit

Average Return

+26.14%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.10% of your transactions generating a profit, with an average return of +26.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VX1 Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VX1 has received 38 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. VX1 average Analyst price target in the past 3 months is 436.64.

Each month's total comprises the sum of three months' worth of ratings.

VX1 Financial Forecast

VX1 Earnings Forecast

Next quarter’s earnings estimate for VX1 is €4.37 with a range of €3.80 to €4.93. The previous quarter’s EPS was €4.09. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Sales Forecast

Next quarter’s sales forecast for VX1 is €2.72B with a range of €2.64B to €2.86B. The previous quarter’s sales results were €2.66B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Stock Forecast FAQ

What is DE:VX1’s average 12-month price target, according to analysts?

Based on analyst ratings, Vertex Pharmaceuticals Inc.’s 12-month average price target is 436.64.

What is DE:VX1’s upside potential, based on the analysts’ average price target?

Vertex Pharmaceuticals Inc. has 13.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Vertex Pharmaceuticals Inc. a Buy, Sell or Hold?

Vertex Pharmaceuticals Inc. has a consensus rating of Moderate Buy, which is based on 16 buy ratings, 6 hold ratings and 0 sell ratings.

What is Vertex Pharmaceuticals Inc.’s share price target?

The average share price target for Vertex Pharmaceuticals Inc. is 436.64. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €515.04 ,and the lowest forecast is €353.03. The average share price target represents 13.11% Increase from the current price of €386.05.

What do analysts say about Vertex Pharmaceuticals Inc.?

Vertex Pharmaceuticals Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Vertex Pharmaceuticals Inc.?

To buy shares of DE:VX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

VX1 Analyst Ratings

VX1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vertex Pharmaceuticals

VX1 Analyst Recommendation Trends

VX1 Financial Forecast

VX1 Earnings Forecast

VX1 Sales Forecast

VX1 Stock Forecast FAQ

Detailed List of Analyst Forecasts